Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMIUC3M)

Drug Name

IMGN901 Drug Info

Synonyms

Lorvotuzumab mertansine

Indication

Disease Entry	ICD 11	Status	REF
Solid tumour/cancer	2A00-2F9Z	Phase 2	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Discontinued Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Neural cell adhesion molecule (NCAM)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
FGLL	DMY61GX	Alzheimer disease	8A20	Phase 1	[3]
ERIC-1	DM08XS2	Solid tumour/cancer	2A00-2F9Z	Terminated	[4]
------------------------------------------------------------------------------------

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Neural cell adhesion molecule (NCAM)	TTUBJQ3	NOUNIPROTAC	Modulator	[2]

------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT02420873) A Study of Lorvotuzumab Mertansine. U.S. National Institutes of Health.
2	Lorvotuzumab mertansine, a CD56-targeting antibody-drug conjugate with potent antitumor activity against small cell lung cancer in human xenograft models. MAbs. 2014 Mar-Apr;6(2):556-66.
3	An NCAM mimetic, FGL, alters hippocampal cellular morphometry in young adult (4 month-old) rats. Neurochem Res. 2013 Jun;38(6):1208-18.
4	Monoclonal antibody UJ13A recognizes the neural cell adhesion molecule (NCAM). Int J Cancer. 1989 Dec 15;44(6):1062-8.